Literature DB >> 9440724

High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.

U Popat1, D Przepiork, R Champlin, W Pugh, K Amin, R Mehra, J Rodriguez, S Giralt, J Romaguera, A Rodriguez, A Preti, B Andersson, I Khouri, D Claxton, M de Lima, M Donato, P Anderlini, J Gajewski, F Cabanillas, K van Besien.   

Abstract

PURPOSE: This study was performed to evaluate the outcome of high-dose chemotherapy and autologous transplantation in patients with diffuse B-cell large-cell lymphoma, and, specifically, to evaluate the impact of primary mediastinal localization on the outcome of high-dose chemotherapy. PATIENTS AND METHODS: A retrospective review was performed of all patients with diffuse large B-cell lymphoma who underwent autologous marrow or peripheral-blood stem-cell transplantation at our institution between January 1 986 and December 1995.
RESULTS: Ninety patients were identified, of whom 31 (34%) had a primary mediastinal B-cell large-cell lymphoma (PML). Cumulative probabilities of disease-free survival, overall survival, and disease progression are 40% (95% confidence interval [CI], 29 to 51), 42% (95% CI, 31 to 53), and 52% (95% CI, 40 to 64), respectively. By univariate analysis, low lactate dehydrogenase (LDH) level and low Ann Arbor stage at transplant were associated with improved survival and disease-free survival. There was a trend for improved disease-free survival and survival for patients with PML. Multivariate stepwise Cox regression analysis showed that LDH level, Ann Arbor stage, and primary mediastinal localization were independent favorable prognostic factors for disease-free survival and survival. LDH level and Ann Arbor stage were also predictive for the risk of disease progression.
CONCLUSION: Our results indicate that patients with PML may display an increased susceptibility to high-dose chemotherapy compared with other types of B-cell large-cell lymphoma. These findings, if confirmed, may have implications for the initial management of patients with PML.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9440724     DOI: 10.1200/JCO.1998.16.1.63

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

2.  Mediastinal huge non-Hodgkin's lymphoma causing compression of the main pulmonary artery trunk.

Authors:  Reiko Mizuno; Shinichi Fujimoto; Yasuyuki Okamoto
Journal:  BMJ Case Rep       Date:  2012-08-02

Review 3.  Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?

Authors:  Kieron Dunleavy; Wyndham H Wilson
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

4.  Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.

Authors:  Santosha Vardhana; Paul A Hamlin; Joanna Yang; Andrew Zelenetz; Craig S Sauter; Matthew J Matasar; Andy Ni; Joachim Yahalom; Craig H Moskowitz
Journal:  Biol Blood Marrow Transplant       Date:  2018-06-15       Impact factor: 5.742

5.  Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan.

Authors:  Naohiro Sekiguchi; Junko Nishimoto; Kazuki Tanimoto; Shigeru Kusumoto; Yasushi Onishi; Takashi Watanabe; Yukio Kobayashi; Hisao Asamura; Yoshikazu Kagami; Yoshihiro Matsuno; Kensei Tobinai
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

6.  Fuzzy neural network applied to gene expression profiling for predicting the prognosis of diffuse large B-cell lymphoma.

Authors:  Tatsuya Ando; Miyuki Suguro; Taizo Hanai; Takeshi Kobayashi; Hiroyuki Honda; Masao Seto
Journal:  Jpn J Cancer Res       Date:  2002-11

7.  Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.

Authors:  Sanghoon Lee; Tishi Shah; Changhong Yin; Jessica Hochberg; Janet Ayello; Erin Morris; Carmella van de Ven; Mitchell S Cairo
Journal:  Oncotarget       Date:  2018-01-18

8.  Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.

Authors:  G Todeschini; S Secchi; E Morra; U Vitolo; E Orlandi; F Pasini; E Gallo; A Ambrosetti; C Tecchio; C Tarella; A Gabbas; A Gallamini; L Gargantini; M Pizzuti; G Fioritoni; L Gottin; G Rossi; M Lazzarino; F Menestrina; M Paulli; M Palestro; M G Cabras; F Di Vito; G Pizzolo
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.